US5084392A - Process for producing optically active hydroxy lactones - Google Patents

Process for producing optically active hydroxy lactones Download PDF

Info

Publication number
US5084392A
US5084392A US07/626,290 US62629090A US5084392A US 5084392 A US5084392 A US 5084392A US 62629090 A US62629090 A US 62629090A US 5084392 A US5084392 A US 5084392A
Authority
US
United States
Prior art keywords
hydroxy group
hydroxy
optically active
ester
butyrolactone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/626,290
Inventor
Kazutoshi Miyazawa
Naoyuki Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JNC Corp
Original Assignee
Chisso Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chisso Corp filed Critical Chisso Corp
Assigned to CHISSO CORPORATION reassignment CHISSO CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MIYAZAWA, KAZUTOSHI, YOSHIDA, NAOYUKI
Application granted granted Critical
Publication of US5084392A publication Critical patent/US5084392A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/003Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
    • C12P41/004Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/04Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Definitions

  • the present invention relates to a process for producing optically active compounds which are used as starting materials for optically active and physiologically active compounds, functional materials, etc., especially optically active hydroxy lactones.
  • Optically active compounds are useful as starting materials for physiologically active compounds such as pharmaceuticals, agricultural chemicals and so on, and functional materials, and as intermediates. However, since the compounds have optical isomers, one of the enantiomers is essentially used in practice. When the racemic compounds or compounds having a low optical purity are used, apparently no compounds having adequate physiological activity or functionality are obtained.
  • Optically active compounds obtained by the process of the present invention namely hydroxy lactones, are very useful compounds. Nevertheless, an effective process of producing the compounds is unknown.
  • the conventional methods have many problems. Firstly, starting materials obtained from natural products via many steps are expensive. Secondarily, since substrate concentration in a process of asymmetrical reduction is very low, the method is unsuitable for mass production. Thirdly, since only either enantiomer is obtainable, the other enantiomer should be obtained by a different method. Fourthly, it is impossible to obtain a compound having high purity.
  • the object of the present invention is to solve the above disadvantages of the conventional methods and to provide a new and useful method for producing optically active hydroxy lactones.
  • the reaction is conducted under anhydrous conditions.
  • This method does not require the use of a small amount of water or a lower alcohol instead of the water, and a side reaction does not occur such as hydrolysis of obtained ester and esters of starting compounds, and formation of undesirable esters scarcely occurs, so that the enzyme is stably kept in organic solvent and easily separated after the reaction and reused.
  • the method can be kept free from contamination by unwanted microorganisms. Accordingly, there is no necessity for special equipment, antiseptics, sterilization treatment, etc. It is possible to conduct the reaction in an open system. Further, the reaction may be conducted in the same or less quantity of solvent in comparison with common organic synthetic reactions in high substrate concentration.
  • esters which are commercially available without any difficulty for transesterification.
  • Ethyl acetate, ethyl propionate, ethyl butyrate, triacetin, tributyrin, tricaproin, etc. can be used.
  • vinyl esters are preferable. Vinyl acetate, vinyl caproate, vinyl laurate, etc. can be exemplified as such vinyl esters.
  • hydrolase can be used, especially a lipase, lipoprotein lipase, esterase, etc., are preferable.
  • the enzyme having the ability to catalyze a transesterification reaction preferentially between the R- or S-compound and the ester when the enzyme is used with the racemic compound can be used regardless of its class.
  • the following table shows commercially available enzymes that can be used in the present reaction.
  • microorganisms which produce the enzymes having the above ability can be used regardless of their species and genus.
  • the genera Arthrobacter, Acromobacter, Alcaligenes, Aspergillus, Chromobacterium, Candida, Mucor, Pseudomonas, Rhizopus, etc. can be exemplified.
  • the enzymes produced from these microorganisms can be used also.
  • racemic compounds represented by the formula (I) of starting materials can be easily prepared by conventional organic chemical methods. For example, the following steps are advantageously used.
  • R 1 is a hydroxy group in the formula (I), ##STR3## wherein R 2 and R 3 are hydrogen or a methyl group, respectively.
  • the compound can be easily obtained by the reaction of the above bromide (II) which is commercially available. (J. Prakt. Chem. 17, 91(1985)).
  • R is alkyl or hydrogen and n is 0 or 1.
  • the diol compound (III) which can be easily obtained by using a common organic chemical method, is reacted under acidic conditions to obtain the lactone.
  • the reaction is conducted by mixing a racemic compound and an ester and by efficiently contacting the mixture with an enzyme.
  • the racemic compound and the ester can be used without any particular treatment.
  • the reaction can be conducted without adding a solvent.
  • an organic solvent such as heptane or toluene may be added.
  • the reaction temperature is suitably 0° to 100° C., and especially preferably 15° to 45° C.
  • the most suitable temperature and the reaction time depend on the kind of the enzyme.
  • the reaction time is 5 to 240 hours.
  • the time can be shortened by elevating the reaction temperature or using an enzyme having high activity or lowering the substrate concentration.
  • racemic compound which is a substrate and the ester are suitably mixed in the ratio 1:0.5 to 1:2 by mole, and preferably 1:1.1 to 1:2.0 by mole.
  • the enzyme can be removed by conventional filter operation and used again, as it is.
  • the reaction can be repeated by fixing the enzyme to absorb on hydrophobic resin or the like.
  • the reactant which is the filtrate can be separated into an optically active alcohol and an optically active ester which is an antipode of the alcohol, respectively, for example by distillation or column chromatography.
  • the ester obtained is hydrolyzed to derive an optically active alcohol which is an antipode of the above alcohol.
  • optically active compounds obtained by the above operation show small difference in optical purities depending on the structures.
  • the optical purities can be raised by re-transesterification reaction.
  • Optically active substances having high purity are obtained by a one-step reaction.
  • the substrate concentration can be increased and big reaction vessels are unnecessary, because a buffer solution and the like are not required in the reaction.
  • optically active compounds prepared by the method of the present invention are important as starting materials of many kinds of useful compounds.
  • S- ⁇ -hydroxy- ⁇ -butyrolactone (1) which can be prepared by the method of the present invention is easily changeable to R- ⁇ -fluoro- ⁇ -butyrolactone (2).
  • the latter compound is useful for a starting material of 1 ⁇ , 25-dihydroxy-24(R)-fluorocholecalsiferol (3) (S. J. Shiuey et al., J. Org. Chem., 53, 1040(1988)).
  • R- ⁇ -hydroxy- ⁇ -butyrolactone which is the antipode of (1) is useful for a starting material of 2,3-epoxy-squalene (M. A. Abdallah et al., J. Chem. Soc., Perkin Trans., 1, 888(1975)). ##STR7##
  • R- ⁇ -hydroxy- ⁇ -butyrolactone (7) is useful for a starting material of the production of (-)-aplysistatine (8) which is an anticancer agent (H. M. Shieh, Tetrahedron Letters, 23, 4643(1981)). ##STR9##
  • S- ⁇ -hydroxy- ⁇ -butyrolactone (9) which can be produced by the method of the present invention is a starting material for synthesizing (-)- ⁇ -multistriatin (10) which is an insect pheromone (M. Larcheveque et al., Tetrahedron, 43, 2303(1987)). ##STR10##
  • the compound (7) from which S-N-benzyloxy-4-acetoxymethyl-2-azetidinone (11) can be derived is usable as an intermediate for producing carbapenem type antibiotics (H. Yamada et al., Heterocycles, 26, 2841(1987)).
  • R- ⁇ -hydroxy- ⁇ -butyrolactone (7) or S- ⁇ -hydroxy- ⁇ -butyrolactone (9) can be converted into R- or S-1,2,4-butanetriol or a derivative thereof.
  • These compounds can be used for synthesizing (+)-ipsdienol (K. Mori et al., Tetrahedron, 35, 933(1979)), mevinolin and compactin (Y. Guindon et al., Tetrahedron Letters, 26, 1185(1985)), S-3-piperidinol (R. K. Olsen et al., J. Org. Chem., 50, 896(1985)), tulipalin B (C. Papageorigiou et al., J.
  • optical purities of the optically active compounds are determined by comparison of specific rotation with compounds having known optical purities in literatures and by HPLC analysis using an optically active resolution column which is commercially available.

Abstract

The invention provides a method for producing an optically active hydroxy lactone which comprises reacting under substantially anhydrous conditions and in the presence of an enzyme an ester and a racemic compound represented by the general formula (I): ##STR1## wherein n is 0 or 1, any one of R1 and R2 is a hydroxy group, and R2 =R3 =H or R2 =R3 =CH3 when R1 is the hydroxy group, and R1 =R3 =H when R2 is the hydroxy group, to effect a transesterification reaction, and resolving to an optically active alcohol which has R- or S-configuration and the ester of the symmetric alcohol.

Description

BACKGROUND OF THE INVENTION
The present invention relates to a process for producing optically active compounds which are used as starting materials for optically active and physiologically active compounds, functional materials, etc., especially optically active hydroxy lactones.
Optically active compounds are useful as starting materials for physiologically active compounds such as pharmaceuticals, agricultural chemicals and so on, and functional materials, and as intermediates. However, since the compounds have optical isomers, one of the enantiomers is essentially used in practice. When the racemic compounds or compounds having a low optical purity are used, apparently no compounds having adequate physiological activity or functionality are obtained.
Optically active compounds obtained by the process of the present invention, namely hydroxy lactones, are very useful compounds. Nevertheless, an effective process of producing the compounds is unknown.
For instance, although a process for preparing derivatives from malic acid or malate obtained in nature is well-known, it is necessary to reduce either of two carboxyl groups or either of two esters. However, an effective process is unknown and the above process is not useful industrially. For obtaining an enantiomer, malic acid as the starting material which is not a natural type should be used. Since the compound is more expensive than that of a natural type, it is disadvantageous industrially for use as the starting material. (K. Mori et al., Tetrahedron, 35, 933(1979), H. Hayashi et al., J. Am. Chem. Soc., 95, 8749(1973), E. J. Corey et al., J. Am. Chem. Soc., 100, 1942(1978), S. J. Shiuey et al , J. Org. Chem., 53, 1040(1988)).
In addition, a process in which L-ascorbic acid is used as a starting material is known. However, the process is troublesome and disadvantageous (K. C. Luk et al., Synthesis, 3, 226(1988)).
Lately, a process for obtaining R-3-hydroxybutyrolactone is found by using baker's yeast. In the process, the effect of an asymmetrical reduction step in which the baker's yeast is used is not good. Namely, for example, one kg of baker's yeast, one kg of sucrose and 8 liters of water are used for treating only 35 g of substrate. The treatment is disadvantageous industrially. In the process, it is impossible to obtain an S-compound. For obtaining the S-compound, the other process should be studied. (D. Seebach, Synthesis, 1, 37(1986)).
Moreover, a method in which a prochiral ketone is asymmetrically reduced with optically active 4-methyl-1,4-dihydro pyridine to obtain S-pantolactone is known. Since the asymmetrical yield is low (about 72% ee), the method is rather impractical. (A. I. Meyers, Tetrahedron Letters, 29, 5617(1988)).
Further, a method for obtaining R- or S-pantolactone by an asymmetric alcoholysis in the presence of lipase has been reported. According to the method, it is possible to obtain both enantiomers. Although, it seems as if the method is excellent, the optical purity of the R-compound is 70% ee and that of S-compound is 36% ee. As a result, the method is impractical. (H. S. Bevinakatti, J. Org. Chem., 54, 2453(1989)).
As described above, the conventional methods have many problems. Firstly, starting materials obtained from natural products via many steps are expensive. Secondarily, since substrate concentration in a process of asymmetrical reduction is very low, the method is unsuitable for mass production. Thirdly, since only either enantiomer is obtainable, the other enantiomer should be obtained by a different method. Fourthly, it is impossible to obtain a compound having high purity.
SUMMARY OF THE INVENTION
The object of the present invention is to solve the above disadvantages of the conventional methods and to provide a new and useful method for producing optically active hydroxy lactones.
The present invention provides a method for producing an optically active hydroxy lactone which comprises reacting under substantially anhydrous conditions and in the presence of an enzyme an ester and a racemic compound represented by the general formula (I): ##STR2## wherein n is 0 or 1, either one of R1 and R2 is a hydroxy group, and R2 =R3 =H or R2 =R3 =CH3 when R1 is the hydroxy group, and R1 =R3 =H when R2 is the hydroxy group, to effect a transesterification reaction, and resolving to an optically active alcohol which has R- or S-configuration and the ester of the symmetric alcohol.
DETAILED DESCRIPTION OF THE INVENTION
In the method of the present invention, the reaction is conducted under anhydrous conditions. This method does not require the use of a small amount of water or a lower alcohol instead of the water, and a side reaction does not occur such as hydrolysis of obtained ester and esters of starting compounds, and formation of undesirable esters scarcely occurs, so that the enzyme is stably kept in organic solvent and easily separated after the reaction and reused. Furthermore, as the enzyme is directly used and reacted in organic solvent, the method can be kept free from contamination by unwanted microorganisms. Accordingly, there is no necessity for special equipment, antiseptics, sterilization treatment, etc. It is possible to conduct the reaction in an open system. Further, the reaction may be conducted in the same or less quantity of solvent in comparison with common organic synthetic reactions in high substrate concentration.
It is also enough to use esters which are commercially available without any difficulty for transesterification. Ethyl acetate, ethyl propionate, ethyl butyrate, triacetin, tributyrin, tricaproin, etc., can be used. Especially, vinyl esters are preferable. Vinyl acetate, vinyl caproate, vinyl laurate, etc. can be exemplified as such vinyl esters.
As the enzyme usable in the present invention, hydrolase can be used, especially a lipase, lipoprotein lipase, esterase, etc., are preferable. However, the enzyme having the ability to catalyze a transesterification reaction preferentially between the R- or S-compound and the ester when the enzyme is used with the racemic compound can be used regardless of its class. For example, the following table shows commercially available enzymes that can be used in the present reaction.
              TABLE                                                       
______________________________________                                    
Trade name                                                                
         Origin           Seller or Maker                                 
______________________________________                                    
Lipase AP                                                                 
         Aspergillus niger                                                
                          Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase M Mucor javanicus  Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase P Pseudomonas fluorescens                                          
                          Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase PS                                                                 
         Pseudomonas fluorescens                                          
                          Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase CES                                                                
         Pseudomonas sp   Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase CE                                                                 
         Humicola lanuginosa                                              
                          Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase AP                                                                 
         Rhizopus javanicus                                               
                          Amano                                           
                          Pharmaceutical                                  
                          Co., Ltd                                        
Lipase II                                                                 
         Porcine pancreas Sigma Chemical                                  
                          Co., Ltd                                        
Lipase VIII                                                               
         Geotrichum candidum                                              
                          Sigma Chemical                                  
                          Co., Ltd                                        
Lipase X Rhizopus delamar Sigma Chemical                                  
                          Co., Ltd                                        
Lipase   Chromobacterium  Toyo Jozo Co., Ltd                              
         viscosum                                                         
Palatase A                                                                
         Aspergillus niger                                                
                          Novo Industi A/S                                
Lipase   Rhizopus niveus  Nagase Biochemi-                                
                          cals, Co. Ltd                                   
Lipase B Pseudomonas flaji                                                
                          Sapporo Beer Co.,                               
                          Ltd                                             
______________________________________                                    
In addition to these enzymes, microorganisms which produce the enzymes having the above ability can be used regardless of their species and genus. As such microorganisms, the genera Arthrobacter, Acromobacter, Alcaligenes, Aspergillus, Chromobacterium, Candida, Mucor, Pseudomonas, Rhizopus, etc., can be exemplified. The enzymes produced from these microorganisms can be used also.
The following description illustrates the process of the present invention more specifically.
In the present invention, the racemic compounds represented by the formula (I) of starting materials can be easily prepared by conventional organic chemical methods. For example, the following steps are advantageously used.
When R1 is a hydroxy group in the formula (I), ##STR3## wherein R2 and R3 are hydrogen or a methyl group, respectively.
Namely, the compound can be easily obtained by the reaction of the above bromide (II) which is commercially available. (J. Prakt. Chem. 17, 91(1985)).
When R2 is a hydroxy group in the formula (I), ##STR4## wherein R1 = R3 = H in the formula (I).
In the above formula, R is alkyl or hydrogen and n is 0 or 1.
Namely, the diol compound (III) which can be easily obtained by using a common organic chemical method, is reacted under acidic conditions to obtain the lactone.
In the present invention, the reaction is conducted by mixing a racemic compound and an ester and by efficiently contacting the mixture with an enzyme.
The racemic compound and the ester can be used without any particular treatment. When the racemic compound which is a substrate is soluble in the ester, the reaction can be conducted without adding a solvent. When the racemic compound is slightly soluble in the ester, an organic solvent such as heptane or toluene may be added.
The reaction temperature is suitably 0° to 100° C., and especially preferably 15° to 45° C. The most suitable temperature and the reaction time depend on the kind of the enzyme.
The reaction time is 5 to 240 hours. The time can be shortened by elevating the reaction temperature or using an enzyme having high activity or lowering the substrate concentration.
The racemic compound which is a substrate and the ester are suitably mixed in the ratio 1:0.5 to 1:2 by mole, and preferably 1:1.1 to 1:2.0 by mole.
After the transesterification reaction, the enzyme can be removed by conventional filter operation and used again, as it is. The reaction can be repeated by fixing the enzyme to absorb on hydrophobic resin or the like. The reactant which is the filtrate can be separated into an optically active alcohol and an optically active ester which is an antipode of the alcohol, respectively, for example by distillation or column chromatography. The ester obtained is hydrolyzed to derive an optically active alcohol which is an antipode of the above alcohol.
The optically active alcohol, which has R- or S-configuration, is represented by the formula: ##STR5## wherein n is 0 or 1, any one of R1 and R2 is a hydroxy group, and R2 =R3 =H or R2 =R3 =CH3 when R1 is the hydroxy group, and R1 =R3 =H when R2 is the hydroxy group, and * shows that the carbon is an asymmetric atom when the carbon binds to the hydroxy group.
The optically active compounds obtained by the above operation show small difference in optical purities depending on the structures. The optical purities can be raised by re-transesterification reaction.
The merits of this invention are as follows.
(1) Unnecessary hydrolysis of esters scarcely occurs because the transesterification reaction is substantially conducted under the conditions of no water.
(2) The enzyme can be easily recovered and reused.
(3) No special equipment and materials are used because the reaction can be performed under the conditions of relatively lower temperatures and an open system.
(4) Optically active substances having high purity are obtained by a one-step reaction.
(5) In spite of the biochemical reaction, the substrate concentration can be increased and big reaction vessels are unnecessary, because a buffer solution and the like are not required in the reaction.
(6) The optically active compounds prepared by the method of the present invention are important as starting materials of many kinds of useful compounds.
The embodiments are shown in the following. ##STR6##
S-α-hydroxy-γ-butyrolactone (1) which can be prepared by the method of the present invention is easily changeable to R-α-fluoro-γ-butyrolactone (2). The latter compound is useful for a starting material of 1α, 25-dihydroxy-24(R)-fluorocholecalsiferol (3) (S. J. Shiuey et al., J. Org. Chem., 53, 1040(1988)).
R-α-hydroxy-γ-butyrolactone which is the antipode of (1) is useful for a starting material of 2,3-epoxy-squalene (M. A. Abdallah et al., J. Chem. Soc., Perkin Trans., 1, 888(1975)). ##STR7##
Further, after a protective substrate is introduced into S-α-hydroxy-γ-butyrolactone (1), ring opening reaction of the compound provides the compound (4) which is a starting mateial for producing mugineic acids (5) and (6) (Japanese Patent Unexamined Publication Nos. 57-112384 and 57-112385). ##STR8##
R-β-hydroxy-γ-butyrolactone (7) is useful for a starting material of the production of (-)-aplysistatine (8) which is an anticancer agent (H. M. Shieh, Tetrahedron Letters, 23, 4643(1981)). ##STR9##
S-β-hydroxy-γ-butyrolactone (9) which can be produced by the method of the present invention is a starting material for synthesizing (-)-α-multistriatin (10) which is an insect pheromone (M. Larcheveque et al., Tetrahedron, 43, 2303(1987)). ##STR10##
Moreover, the compound (7) from which S-N-benzyloxy-4-acetoxymethyl-2-azetidinone (11) can be derived is usable as an intermediate for producing carbapenem type antibiotics (H. Yamada et al., Heterocycles, 26, 2841(1987)).
Further, R-β-hydroxy-γ-butyrolactone (7) or S-β-hydroxy-γ-butyrolactone (9) can be converted into R- or S-1,2,4-butanetriol or a derivative thereof. These compounds can be used for synthesizing (+)-ipsdienol (K. Mori et al., Tetrahedron, 35, 933(1979)), mevinolin and compactin (Y. Guindon et al., Tetrahedron Letters, 26, 1185(1985)), S-3-piperidinol (R. K. Olsen et al., J. Org. Chem., 50, 896(1985)), tulipalin B (C. Papageorigiou et al., J. Org. Chem., 50, 1144(1985), aglycone (S. Hanessian et al., J. Org. Chem., 48, 4427(1983)), dihydroxypentyluracil (H. Hayashi et al., J. Am. Chem. Soc., 95, 8749(1973)), etc.
DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention is illustrated by the following examples. In the examples, the optical purities of the optically active compounds are determined by comparison of specific rotation with compounds having known optical purities in literatures and by HPLC analysis using an optically active resolution column which is commercially available.
EXAMPLE 1
Optical resolution of α-hydroxy-γ-butyrolactone (in formula (I), n=0, R1 =OH and R2 =R3 =H).
(i) A mixture of 2.0 g of racemic α-hydroxy-γ-butyrolactone, 1.01 g of vinyl acetate and 0.2 g of lipase PS (manufactured by Amano Pharmaceutical Co., Ltd.) was reacted with stirring at 20° C. for 75 hours. After the reaction was stopped, the enzyme was removed by suction filtration, and the residue was purified with a chromatograph over silica gel to obtain 1.09 g of S-α-hydroxy-γ-butyrolactone, [α]D 26 -37.1°(C 1.18, CHC13) and 1.3 g of R-α-acetoxy-γ-butyrolactone. 5 ml of ethanol and 3 drops of concentrated sulfuric acid were added to 1.3 g of R-α-acetoxy-γ-butyrolactone. The mixture was reacted with stirring at 40° C. for 5 hours and deacetylated. 0.84 g of R-α-hydroxy-γ-butyrolactone (yield: 84%) was obtained. 93% ee.
[α]D 30 +61.2°(C 1.07, CHC13) 1 H-NMR δ2.1-2.8(m, 2H, CH2), δ3.15(brs, 1H, OH), 4.1-4.7 (m, 3H, CH2 O, CHO)
(ii) 0.5 g of vinyl acetate and 0.1 g of lipase PS were added to 1.09 g of S-α-hydroxy-γ-butyrolactone obtained in (i). The mixture was reacted with stirring at 20° C. for 50 hours. After the reaction was stopped, the enzyme was removed by suction filtration, and the residue was purified with a chromatograph over silica gel to obtain 0.75 g of S-α-hydroxy-γ-butyrolactone (yield: 75%). 97.1% ee.
[α]D 26 -63.3°(C 1.18, CHC13).
(Literature value: [α D 25 -65.2°(C 1.15, CHC13), S. J. Shiuey et al., J. Org. Chem., 53, 1040(1988)).
EXAMPLE 2
Optical resolution of α-hydroxy-β-dimethyl-γ-butyrolactone (pantolactone)(in formula (I), n=0, R1 =OH and R2 =R3 =H).
A mixture of 2.0 g of racemic α-hydroxy-β-dimethyl-γ-butyrolactone (pantolactone), 0.80 g of vinYl acetate, 1.0 g of lipase PS (manufactured by Amano pharmaceutical Co., Ltd.) and 6 ml of toluene was reacted with stirring at 20° C. for 150 hours. After the reaction was stopped, the enzyme was removed by suction filtration, and the residue was purified with a chromatograph over silica gel to obtain 1.1 g of S-α-acetoxy-β-dimethyl-γ-butyrolactone [(yield: 85%). 96.4% ee. [α]D 27 +13.5°(C 1.26, EtOH). (Literature value: [α]D 25 +14.0°(EtOH), S. Nabeta et al., Ger. Offen. 1948368 (1970)] and 0.71 g of R-α-hydroxy-β-dimethyl-γ-butyrolactone (yield: 71%). 80.1% ee.
[α]D 28 -40.6°(C 1.05, H2 O).
(Literature value: [α]D 25 -50.7°(C 2.05, H2 O), I. Ojima et al., Org. Synthesis, 63, 18(1984)).
EXAMPLE 3
Optical resolution of β-hydroxy-γ-butyrolactone (in formula (I), n=0, R2 =OH and R1 =R3 =H).
(i) A mixture of 1.0 g of racemic β-hydroxy-γ-butyrolactone, 0.5 g of vinyl acetate and 0.1 g of lipase PS (manufactured by Amano Pharmaceutical Co., Ltd.) was reacted with stirring at 25° C. for 48 hours. After the reaction was stopped, the enzyme was removed by suction filtration, and the residue was purified with a chromatograph over silica gel to obtain 0.32 g of S-β-hydroxy-γ-butyrolactone [α D 28 -19.7°(C 1.15, EtOH) and 0.35 g of R-β-acetoxy-γ-butyrolactone. To the S-compound, 5 ml of THF and 1 ml of an aqueous solution of 18N-H2 SO4 were added. The mixture was reacted with stirring for 24 hours to obtain 0.25 g of deacetylated R-β-hydroxy-γ-butyrolactone. Yeild: 50%. 48.1% ee.
1 H-NMR(CDC13 /TMS)
δ62.52(dm, 1H, J=20Hz), 2.74(dd, 1H, J=20.7Hz), 3.02(d, 1H, J=4Hz), 4.30(dm, 1H, J=12Hz), 4.42(dm, 1H, J=12.5Hz), 4.67(m, 1H)
(ii) 0.16 g of vinyl acetate and 0.1 g of lipase PS were added to 0.32 g of S-β-hydroxy-γ-butyrolactone obtained in (i). The mixture was reacted with stirring at 25° C. for 48 hours. After the reaction was stopped, the enzyme was removed by suction filtration, and the residue was purified with a chromatograph over silica gel to obtain 0.20 g of S-β-hydroxy-γ-butyrolactone (yield: 40%). 85% ee.
[α]D 28 +65.7°(C 0.90, EtOH). (Literature value: R-β-hydroxy-γ-butyrolactone [α]D 23 +77.3°(C 2.0, EtOH), K. Mori et al., Tetrahedron, 35, 933(1979)).

Claims (4)

We claim:
1. A process for producing an optically active hydroxy lactone, which comprises reacting under substantially anhydrous conditions and in the presence of an enzyme having the ability to catalyze a transesterification reaction, an ester which can be transesterified and a racemic compound represented by the general formula (I): ##STR11## wherein n is 0 or 1, either one of R1 and R2 is a hydroxy group, and R2 =R3 =H or R2 =R3 =CH3 when R1 is the hydroxy group, and R1 =R3 =H when R2 is the hydroxy group, to effect a transesterification reaction, and resolving to (1) an optically active alcohol which has R- or S-configuration represented by the formula: ##STR12## wherein n is 0 or 1, either one of R1 and R2 is a hydroxy group, and R2 =R3 =H or R2 =R3 =CH3 when R1 is the hydroxy group, and R1 =R3 =H when R2 is the hydroxy group, and * shows that the carbon is an asymmetric atom when the carbon binds to the hydroxy group, and (2) the ester of the enantiomeric alcohol.
2. The process as claimed in claim 1, wherein the enzyme is lipase.
3. The process as claimed in claim 1, wherein the ester is a vinyl ester.
4. The process as claimed in claim 3, wherein the vinyl ester is vinyl acetate.
US07/626,290 1990-02-02 1990-12-12 Process for producing optically active hydroxy lactones Expired - Lifetime US5084392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2-22054 1990-02-02
JP2022054A JP2542941B2 (en) 1990-02-02 1990-02-02 Method for producing optically active hydroxy lactones

Publications (1)

Publication Number Publication Date
US5084392A true US5084392A (en) 1992-01-28

Family

ID=12072203

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/626,290 Expired - Lifetime US5084392A (en) 1990-02-02 1990-12-12 Process for producing optically active hydroxy lactones

Country Status (4)

Country Link
US (1) US5084392A (en)
EP (1) EP0439779B1 (en)
JP (1) JP2542941B2 (en)
DE (1) DE69021711T2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225817A1 (en) * 1992-08-05 1994-02-10 Chemie Linz Deutschland Sepn. of racemic mixt. of delta valerolactone derivs. - by reacting a soln. of the racemic cpd. with a hydrolase, opt. in the presence of an esterifying agent to convert (2R,3R,5S) enantiomer to the (2S,3S,5R) enantiomer
US5296220A (en) * 1992-12-07 1994-03-22 Roelofs Wendell L Cockroach attractant
US5372940A (en) * 1990-10-05 1994-12-13 Fuji Yakuhin Kogyo Kabushiki Kaisha D-pantolactone hydrolase and process for the preparation thereof
US5412110A (en) * 1992-07-06 1995-05-02 Chemie Linz Gesellschaft M.B.H. Enzymatic process to separate racemic mixtures of delta valerolactones
US5413935A (en) * 1991-04-24 1995-05-09 E. R. Squibb & Sons, Inc. Process for selecting an enantiomer of a hydroxy lactone using pseudomonas lipase
US5574182A (en) * 1989-11-14 1996-11-12 Chisso Corporation Optically active compounds having plural chiral centers and production thereof
US20040072893A1 (en) * 2001-01-19 2004-04-15 Sumitra Srinath Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
WO2007035066A1 (en) * 2005-09-26 2007-03-29 Enzytech, Ltd. The method of making optically active 3-acyloxy-gamma-butyrolactone and optically active 3-hydroxy-gamma-butyrolactone by enzymatic method
WO2007100227A1 (en) * 2006-03-02 2007-09-07 Lg Chem, Ltd. Method for preparing (s)-3-hydroxy-gamma-butyrolactone using hydrolase

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4005150A1 (en) * 1990-02-17 1991-08-22 Hoechst Ag METHOD FOR THE ENZYMATIC RACEMATE CLEAVAGE OF PANTOLACTON
WO1993006235A1 (en) * 1991-09-20 1993-04-01 Zeneca Limited Process for the preparation of enantiomerically pure 4-hydroxytetrahydro-2-pyranone derivatives
JPH07507200A (en) * 1991-09-20 1995-08-10 ゼネカ リミテッド pyranon
WO2001018231A2 (en) * 1999-09-08 2001-03-15 Lonza Ag METHOD FOR PRODUCING (R) OR (S)-HYDROXY-η-BUTYROLACTONE
KR100618724B1 (en) * 2001-09-12 2006-08-31 미쯔비시 레이온 가부시끼가이샤 Process for producing monomer
US7632948B2 (en) 2002-08-22 2009-12-15 Neurosearch A/S Method of preparing enantiomers of indole-2,3-dione-3-oxime derivatives
KR100657204B1 (en) * 2004-07-23 2006-12-14 엔자이텍 주식회사 The method of making optically active 3-hydroxy-?-butyrolactone by enzymatic method

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489208A (en) * 1979-10-17 1984-12-18 E.N.I. Nazionale Idrocarburi Process for producing D(-)mandelic acid
JPS6410996A (en) * 1987-02-06 1989-01-13 Idemitsu Kosan Co Production of alpha-hydroxy-beta,beta-dimethyl-gamma-butyrolactone
EP0337920A2 (en) * 1988-04-14 1989-10-18 Hoechst Aktiengesellschaft Process for high regioselective esterification and ether-cleavage on unsaturated sugar compounds with the help of lipases and esterases and products obtained with that process
US4916074A (en) * 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
EP0371568A1 (en) * 1988-12-01 1990-06-06 Unilever N.V. Process for producing gamma-lactones
US4962031A (en) * 1987-05-01 1990-10-09 Chisso Corporation Process for producing optically active compounds
US4971909A (en) * 1987-08-28 1990-11-20 Chisso Corporation Process for producing optically active compounds having pyridine skeletons

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3743824C2 (en) * 1987-12-23 1997-03-06 Hoechst Ag Process for the enzymatic resolution of racemic alcohols with / in vinyl esters by transesterification
DE4005150A1 (en) * 1990-02-17 1991-08-22 Hoechst Ag METHOD FOR THE ENZYMATIC RACEMATE CLEAVAGE OF PANTOLACTON

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489208A (en) * 1979-10-17 1984-12-18 E.N.I. Nazionale Idrocarburi Process for producing D(-)mandelic acid
US4916074A (en) * 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
JPS6410996A (en) * 1987-02-06 1989-01-13 Idemitsu Kosan Co Production of alpha-hydroxy-beta,beta-dimethyl-gamma-butyrolactone
US4962031A (en) * 1987-05-01 1990-10-09 Chisso Corporation Process for producing optically active compounds
US4971909A (en) * 1987-08-28 1990-11-20 Chisso Corporation Process for producing optically active compounds having pyridine skeletons
EP0337920A2 (en) * 1988-04-14 1989-10-18 Hoechst Aktiengesellschaft Process for high regioselective esterification and ether-cleavage on unsaturated sugar compounds with the help of lipases and esterases and products obtained with that process
EP0371568A1 (en) * 1988-12-01 1990-06-06 Unilever N.V. Process for producing gamma-lactones

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Bevinakatti, J. Org. Chem., 54, 2453 (1989). *
Hayashi et al., J. Am. Chem. Soc., 95, 8749 (1973). *
Luk et al., Synthesis, 3, 226 (1988). *
Meyers, Tetrahedron Letters, 29, 5617 (1988). *
Mori et al., Tetrahedron, 35, 933 (1979). *
Seebach, Synthesis, 1, 37 (1986). *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574182A (en) * 1989-11-14 1996-11-12 Chisso Corporation Optically active compounds having plural chiral centers and production thereof
US5372940A (en) * 1990-10-05 1994-12-13 Fuji Yakuhin Kogyo Kabushiki Kaisha D-pantolactone hydrolase and process for the preparation thereof
US5413935A (en) * 1991-04-24 1995-05-09 E. R. Squibb & Sons, Inc. Process for selecting an enantiomer of a hydroxy lactone using pseudomonas lipase
US5412110A (en) * 1992-07-06 1995-05-02 Chemie Linz Gesellschaft M.B.H. Enzymatic process to separate racemic mixtures of delta valerolactones
DE4225817A1 (en) * 1992-08-05 1994-02-10 Chemie Linz Deutschland Sepn. of racemic mixt. of delta valerolactone derivs. - by reacting a soln. of the racemic cpd. with a hydrolase, opt. in the presence of an esterifying agent to convert (2R,3R,5S) enantiomer to the (2S,3S,5R) enantiomer
US5296220A (en) * 1992-12-07 1994-03-22 Roelofs Wendell L Cockroach attractant
US20040072893A1 (en) * 2001-01-19 2004-04-15 Sumitra Srinath Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
US6867306B2 (en) 2001-01-19 2005-03-15 Biocon Limited Process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
WO2007035066A1 (en) * 2005-09-26 2007-03-29 Enzytech, Ltd. The method of making optically active 3-acyloxy-gamma-butyrolactone and optically active 3-hydroxy-gamma-butyrolactone by enzymatic method
WO2007100227A1 (en) * 2006-03-02 2007-09-07 Lg Chem, Ltd. Method for preparing (s)-3-hydroxy-gamma-butyrolactone using hydrolase
US20090104669A1 (en) * 2006-03-02 2009-04-23 Oh-Jin Park Method for Preparing (S)-3-Hydroxy-Gamma-Butyrolactone Using Hydrolase

Also Published As

Publication number Publication date
EP0439779A2 (en) 1991-08-07
EP0439779B1 (en) 1995-08-16
DE69021711T2 (en) 1996-02-22
EP0439779A3 (en) 1992-08-05
JPH03228694A (en) 1991-10-09
DE69021711D1 (en) 1995-09-21
JP2542941B2 (en) 1996-10-09

Similar Documents

Publication Publication Date Title
US5084392A (en) Process for producing optically active hydroxy lactones
US4962031A (en) Process for producing optically active compounds
EP0501310B1 (en) Method for optical resolution of corey lactone diols
JPH0436195A (en) Production of optically active alpha-hydroxyesters
EP0774452B1 (en) Optically active compounds having plural chiral centers and the production thereof
AU670088B2 (en) Enzymatic process to separate racemic mixtures of delta valerolactones
US5128252A (en) Process for producing optically active compound
US5256569A (en) Transesterification process for otereoselection of enantiomers of secondary alcohols using pseudomonas lipase with no added solvent
US5534436A (en) Enzymatic resolution of asymmetric alcohols by means of vinyl esters of polybasic carboxylic acids
US5493063A (en) Process for optical resolution of 1,2-diol derivatives
EP0451668B1 (en) Process for the production of optically active alkyl 3-aryl-3-hydroxypropionates
US5324852A (en) 4-Substituted-2-hydroxybutanoates and a process for producing them
US5391494A (en) Process for selectively producing optically active 1-derivatized-2-diol using lipase CES and triglyceride
JP2726114B2 (en) Process for producing optically active 3-chloro-1,2-propanediol and its esters
US5089176A (en) Optically active monoester compounds and producing
US20020025565A1 (en) Method for optically resolving a racemic alpha-substituted heterocyclic carboxylic acid using enzyme
US5643793A (en) Method for producing optically active 3-hydroxyhexanoic acids using porcine pancreatic lipase
JP2690953B2 (en) Process for producing optically active 1,3-butanediol and its derivatives
US5272069A (en) Method of producing optically active hydroxyesters
US5750382A (en) Process for producing optically active 2-alkoxycyclohexanol derivatives
US5202457A (en) Optically active alkyl 3-aryl-3-hydroxypropionates and a method for producing thereof
JP3095539B2 (en) Process for producing optically active α, β-epoxycarboxylic acid and its ester
EP0576002B1 (en) Optically active 2-alkoxy-carbonyl-2-cycloalkene derivatives and a process for producing the derivatives
JPH08119958A (en) Production of optically active chroman compound
JPH04258297A (en) Production of optically active 1-phenyl-1,3-propanediol and its derivative

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHISSO CORPORATION, 6-32, NAKANOSHIMA 3-CHOME, KIT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:MIYAZAWA, KAZUTOSHI;YOSHIDA, NAOYUKI;REEL/FRAME:005538/0117

Effective date: 19901203

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12